Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3361 - Serum interleukin-6 as a prognostic biomarker for survival in patients with unresectable pancreatic cancer


10 Oct 2016


Poster display


Inna Chen


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


I. Chen1, C. Dehlendorff2, P. Pfeiffer3, B.V. Jensen1, S.E. Nielsen1, N.H. Holländer4, M.K. Yilmaz5, J. Johansen1

Author affiliations

  • 1 Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Research Center, Danish Cancer Society Institute of Cancer Biology, 2100 - Copenhagen/DK
  • 3 Department Of Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 4 Oncology, Zealand University Hospital, 4700 - Naestved/DK
  • 5 Department Of Oncology, Aalborg University Hospital, 9100 - Aalborg/DK


Abstract 3361


Patients with pancreatic cancer (PC) have the highest mortality rate of all major cancers. Interleukin-6 (IL-6) is produced by PC cells and macrophages, regulates inflammation and plays an important role in cachexia. The aim of this biomarker study was to determine the clinical utility of serum IL-6 as a prognostic factor. We further explored age, sex, CA 19.9, PS, stage and chemotherapy type as predictors of outcome in patients receiving palliative chemotherapy.


452 patients with unresectable PC (M/F: 242/210; median age 67.5 (IQR 61.8, 73.0); ECOG Performance Status (PS) of 0/1/2: 150/247/55; locally advanced disease/metastatic: 97/355; treated with gemcitabine n = 337, FOLFIRINOX n= 83, gemcitabine and nab-Paclitaxel n = 14 or capecitabine-containing regimens n = 18) were included in the BIOPAC study from five hospitals in Denmark (2008-2016). Pretreatment and longitudinal serum CA 19.9 (Siemens) and IL-6 were determined (ELISA, R&D Systems).


Patients were grouped into quartiles according to baseline IL-6 values (0.8 to 3.2, 3.2 to 6.4, 6.4 to 14, and ≥14 pg/ml) and CA 19.9 values (1 to 119, 119 to 992, 992 to 7280, and 7280 to 687.000 U/ml. On univariate analysis, IL-6 ≥6.4 pg/ml, CA 19.9, PS, stage, chemotherapy type were identified as significant risk factors for overall survival (OS). Hazard ratio (HR) in quartiles with lowest quartile as reference were 1.20 (95% confidence interval (CI), 0.91–1.57; P = 0.19), 1.87 (95% CI, 1.43–2.46; P 


The serum level of IL-6 is a strong independent prognostic biomarker in patients with unresectable PC that could be used to identify patients with poor outcome. Changes in IL-6 from baseline are predictive for survival.

Clinical trial identification

Ethics committee (nr. KA-20060113). Danish Data Protection Agency (j.nr. 2012-58-0004; HGH-2015-027; I-Suite nr:03960)

Legal entity responsible for the study

Inna Chen


Herlev Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings